The optimal intravesical maintenance chemotherapy scheme for the intermediate-risk group non-muscle-invasive bladder cancer

Although the current European Association of Urology(EAU) guideline recommends that patients with intermediate-risk non-muscle-invasive bladder cancer (NMIBC) should accept intravesical chemotherapy or CalmetteGuerin (BCG) for no more than one year after transurethral resection of bladder tumor (TURBT), there is no consensus on the optimal duration of chemotherapy.